EP1309325A1 — Anticonvulsant derivatives useful for the treatment of depression
Assigned to Janssen Pharmaceuticals Inc · Expires 2003-05-14 · 23y expired
What this patent protects
Anticonvulsant derivatives of formula (I) for the treating depression as monotherapy or combination therapy are disclosed. Wherein X is CH2 or oxygen; R1 is hydrogen or alkyl; and R?2, R3, R4 and R5¿ are independently hydrogen or lower alkyl and, when X is CH¿2?, R?4 and R5¿ may …
USPTO Abstract
Anticonvulsant derivatives of formula (I) for the treating depression as monotherapy or combination therapy are disclosed. Wherein X is CH2 or oxygen; R1 is hydrogen or alkyl; and R?2, R3, R4 and R5¿ are independently hydrogen or lower alkyl and, when X is CH¿2?, R?4 and R5¿ may be alkene groups joined to form a benzene ring and, when X is oxygen, R?2 and R3¿ and/or R?4 and R5¿ together may be a methylenedioxy group of the following formula (II): wherein R?6 and R7¿ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.